Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Tabea Wilhelm et al.|The Lancet Oncology|2012Cited by 906
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Douglas B. Johnson et al.|Annals of Oncology|2016Cited by 822
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Carrie R. Daniel et al.|The Lancet Oncology|2018Cited by 658
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|Cancer Cell|2022Cited by 338
A novel AKT3 mutation in melanoma tumours and cell linesMichael A. Davies, Gordon B. Mills|British Journal of Cancer|2008Cited by 267